STOCK TITAN

Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Annovis Bio (NYSE: ANVS) received a second consecutive positive independent safety-board recommendation for its Phase 3 DUET-AD trial in early Alzheimer’s disease.

The Data and Safety Monitoring Board recommended continuing without modification after its 12-month review. It assessed safety data accumulated through September 22, 2026, from 861 patients at different stages of dosing. This follows positive 6-month feedback announced in February 2026.

The trial evaluates buntanetap, an investigational once-daily pill. Annovis expects the last patient’s last visit for the 6-month treatment period on December 31, 2026, database lock on February 8, 2027, and 6-month topline results in March 2027, with detailed safety outcomes alongside symptomatic results. The company is also preparing for regulatory submission.

Loading...
Loading translation...

Positive

  • Minor pointSecond consecutive positive safety-board recommendation supports continuing DUET-AD without modification after review of 861 patients’ safety data.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Six-month topline results remain expected in March 2027, alongside detailed safety outcomes.
  • Minor pointRegulatory submission preparations are underway at Annovis.

Negative

  • None.

Key Figures

Patients reviewed: 861 patients Review period: 12 months Last patient, last visit: December 31, 2026 +2 more
Patients reviewed
861 patients
Safety data accumulated through September 22, 2026
Review period
12 months
Second DSMB review of DUET-AD
Last patient, last visit
December 31, 2026
Expected end of the 6-month treatment period
Database lock
February 8, 2027
DUET-AD
6-month topline results
March 2027
DUET-AD

Previous Clinical trial Reports

1 past event · Latest: Feb 12
Same Type 1 event
  1. Feb 12

    DSMB safety recommendation

    24h Move
    +2.5%

    DSMB recommended the Phase 3 Alzheimer’s trial continue without modification after its six-month safety review.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dsmb, database lock
2 terms
dsmb medical
"independent Data and Safety Monitoring Board (DSMB)"
A DSMB (Data and Safety Monitoring Board) is an independent group of medical and statistical experts that watches over clinical trials to protect participants and ensure the study’s data are reliable. Think of it as an impartial referee who can pause, change, or stop a trial if safety problems, clear benefits, or data flaws appear; its decisions can quickly alter a biotech company’s regulatory path, market value, and investor outlook.
database lock technical
"database lock on February 8, 2027"
A database lock is the point in a clinical trial when the collected study data are finalized and no further changes or corrections are allowed, so analysts can run the official statistical tests. For investors this matters because it usually precedes public results or regulatory filings—think of it like sealing and signing off an exam before grading: once locked, the timing and content of the readout become clearer and uncertainty about last-minute data edits is reduced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company’s pivotal Phase 3 trial in early AD, after the review of the study’s safety data. This 12-month review follows the DSMB’s positive 6-month feedback, which was announced in February 2026.

The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing.

“A second positive recommendation from the DSMB in such a large population further reinforces our confidence in buntanetap’s safety profile,” said Cheng Fang, Ph.D., Chief Scientific Officer at Annovis. “This milestone comes at an important time. As we approach the 6-month data readout and prepare for regulatory submission, a demonstrated safety at scale is essential. In March, we will report detailed DUET-AD safety outcomes alongside the 6-month symptomatic results.”

DUET-AD (NCT06709014) remains on track, with last patient, last visit for the 6-month treatment period expected on December 31, 2026, database lock on February 8, 2027, and 6-month topline results in March 2027.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the safety board recommend for Annovis Bio’s DUET-AD trial?

The independent Data and Safety Monitoring Board recommended that DUET-AD continue without modification. Its 12-month review covered safety data accumulated through September 22, 2026, from 861 patients at different stages of dosing. This was its second consecutive positive recommendation.

When does Annovis Bio expect DUET-AD six-month results?

Annovis expects 6-month topline results in March 2027, with detailed safety outcomes alongside symptomatic results. The last patient’s last visit for the 6-month treatment period is expected on December 31, 2026, followed by database lock on February 8, 2027.

Keep reading